Merck & Co. Files 8-K on Financials and Exit Costs

Ticker: MRK · Form: 8-K · Filed: 2025-07-29T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, disposal-activities, sec-filing

Related Tickers: MRK

TL;DR

Merck dropped an 8-K detailing Q3 financials and exit costs. Check the filings for the full scoop.

AI Summary

Merck & Co., Inc. filed an 8-K on July 29, 2025, reporting results of operations and financial condition as of July 25, 2025. The filing also details costs associated with exit or disposal activities and includes financial statements and exhibits. Specific financial figures and details regarding these activities are provided within the document.

Why It Matters

This filing provides investors with crucial updates on Merck's financial performance and any significant restructuring or disposal activities, impacting the company's future financial health.

Risk Assessment

Risk Level: medium — The filing concerns financial results and potential restructuring costs, which can introduce volatility and uncertainty for investors.

Key Players & Entities

FAQ

What specific financial results are being reported by Merck & Co., Inc. in this 8-K?

The 8-K filing indicates that it reports on 'Results of Operations and Financial Condition' as of July 25, 2025, but the specific financial figures are detailed within the document itself.

What kind of 'Cost Associated with Exit or Disposal Activities' is Merck & Co., Inc. disclosing?

The filing states that it covers 'Cost Associated with Exit or Disposal Activities,' with the specific nature and amount of these costs detailed within the full document.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on July 29, 2025.

What is the primary purpose of this 8-K filing for Merck & Co., Inc.?

The primary purpose is to report on the company's results of operations and financial condition, as well as any costs associated with exit or disposal activities, and to include relevant financial statements and exhibits.

What is Merck & Co., Inc.'s fiscal year end?

Merck & Co., Inc.'s fiscal year ends on December 31.

From the Filing

0001104659-25-071380.txt : 20250729 0001104659-25-071380.hdr.sgml : 20250729 20250729064243 ACCESSION NUMBER: 0001104659-25-071380 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250725 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250729 DATE AS OF CHANGE: 20250729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 251157462 BUSINESS ADDRESS: STREET 1: 126 EAST LINCOLN AVENUE STREET 2: P.O. BOX 2000 CITY: RAHWAY STATE: NJ ZIP: 07065 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 126 EAST LINCOLN AVENUE STREET 2: P.O. BOX 2000 CITY: RAHWAY STATE: NJ ZIP: 07065 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 8-K 1 tm2521736d1_8k.htm FORM 8-K false 0000310158 0000310158 2025-07-25 2025-07-25 0000310158 us-gaap:CommonStockMember 2025-07-25 2025-07-25 0000310158 mrk:Sec1.875NotesDue2026Member 2025-07-25 2025-07-25 0000310158 mrk:Sec3.250NotesDue2032Member 2025-07-25 2025-07-25 0000310158 mrk:Sec2.500NotesDue2034Member 2025-07-25 2025-07-25 0000310158 mrk:Sec1.375NotesDue2036Member 2025-07-25 2025-07-25 0000310158 mrk:Sec3.500NotesDue2037Member 2025-07-25 2025-07-25 0000310158 mrk:Sec3.700NotesDue2044Member 2025-07-25 2025-07-25 0000310158 mrk:Sec3.750NotesDue2054Member 2025-07-25 2025-07-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) July 29, 2025 ( July 25, 2025 )   Merck & Co., Inc. (Exact name of registrant as specified in its charter)   New Jersey (State or other jurisdiction of incorporation)   1-6571 (Commission File Number)   22-1918501 (I.R.S. Employer Identification No.)   126 East Lincoln Avenue , Rahway , NJ (Address of principal executive offices)   07065 (Zip Code)   Registrant’s telephone number, including area code ( 732 ) 594-4000   Not Applicable (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock ($0.50 par value)   MRK   New York Stock Exchange 1.875% Notes due 2026   MRK/26   New York Stock Exchange 3.250% Notes due 2032   MRK/32   New York Stock Exchange 2.500% Notes due 2034   MRK/34   New York Stock Exchange 1.375% Notes due 2036   MRK 36A   New York Stock Exchange 3.500% Notes due 2037   MRK/37   New York Stock Exchange 3.700% Notes due 2044   MRK/44   New York Stock Exchange 3.750% Notes due 2054   MRK/54   New Yor

View on Read The Filing